• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Conclusions:The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities. PMID: 25589625 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 14, 2015 Category: Cancer & Oncology Authors: Baeumer S, Baeumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C Tags: Clin Cancer Res Source Type: research

HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF mutant colorectal cancer by down-regulation of c-FLIPL.
CONCLUSIONS: Our findings indicate that c-MET/STAT3-dependent upregulation of c-FLIPL expression is an important escape mechanism following MEKi treatment in BRAFMT CRC. Thus, combinations of MEKi with inhibitors of c-MET or c-FLIP (eg. HDAC inhibitors) could be potential novel treatment strategies for BRAFMT CRC. PMID: 25813020 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 26, 2015 Category: Cancer & Oncology Authors: Carson R, Celtikci B, Fenning CS, Javadi A, Crawford N, Perez-Carbonell L, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S Tags: Clin Cancer Res Source Type: research

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
CONCLUSIONS: We demonstrate that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistance to BRAF inhibitors in BRAFV600E CRC, and suggest combinatorial approaches to improve outcomes in this poor prognosis subset of patients. PMID: 23251002 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 18, 2012 Category: Cancer & Oncology Authors: Mao M, Tian F, Mariadason JM, Tsao L, Lemos R, Dayyani F, Yennu Nanda VG, Jiang ZQ, Wistuba I, Tang X, Bornmann WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S Tags: Clin Cancer Res Source Type: research

Increased TGFα as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
CONCLUSIONS: These results suggest that overexpression of TGFα through induction of EGFR-MET interaction contributes to cetuximab resistance in CRC cells. PMID: 24122793 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 11, 2013 Category: Cancer & Oncology Authors: Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'aiuto E, Berrino L, Bianco R, Ciardiello F Tags: Clin Cancer Res Source Type: research

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
CONCLUSION: These results suggest that activation of MEK is involved in both primary and acquired resistance to cetuximab and the inhibition of EGFR and MEK could be a strategy for overcoming anti-EGFR resistance in CRC patients. PMID: 24812410 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 8, 2014 Category: Cancer & Oncology Authors: Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E Tags: Clin Cancer Res Source Type: research

Elevated serum angiopoietin-like protein 2 correlates with the metastatic properties of colorectal cancer: a serum biomarker for early diagnosis and recurrence.
Conclusions:Serum ANGPTL2 is a novel diagnostic and recurrence-predictive biomarker in patients with CRC. PMID: 25294915 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 7, 2014 Category: Cancer & Oncology Authors: Toiyama Y, Tanaka K, Kitajima T, Shimura T, Kawamura M, Kawamoto A, Okugawa Y, Saigusa S, Hiro J, Inoue Y, Mohri Y, Goel A, Kusunoki M Tags: Clin Cancer Res Source Type: research

Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer.
CONCLUSIONS: Impaired RCC2 affects functional and clinical endpoints of CRC. High-risk patients with either MSI or MSS tumors can be identified with cost-effective routine RCC2 assays. PMID: 25910952 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 24, 2015 Category: Cancer & Oncology Authors: Bruun J, Kolberg M, Ahlquist TC, Royrvik E, Nome T, Leithe E, Lind GE, Merok MA, Rognum TO, Bjorkoy G, Johansen T, Lindblom A, Sun XF, Svindland A, Liestol K, Nesbakken A, Skotheim RI, Lothe RA Tags: Clin Cancer Res Source Type: research

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
CONCLUSION: We have characterized at the transcriptomic level the differences between colorectal cancer cells that vary in their growth rates, and identified novel candidate chemotherapeutic targets for the treatment of colorectal cancer. PMID: 25944804 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 5, 2015 Category: Cancer & Oncology Authors: Bazzocco S, Andretta E, Rodrigues P, Garrido M, Alazzouzi H, Chionh F, Carton-Garcia F, Macaya I, Nieto R, Sanchez A, Schwartz S, Dopeso H, Bilic J, Mariadason JM, Arango D Tags: Clin Cancer Res Source Type: research

Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
CONCLUSION: XPO5 acts like an oncogene in CRC by regulating the expression of miRNAs and may be a potential therapeutic target in CRC. PMID: 27553833 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 22, 2016 Category: Cancer & Oncology Authors: Shigeyasu K, Okugawa Y, Toden S, Boland CR, Goel A Tags: Clin Cancer Res Source Type: research